Compound A Methods for RAS Protein-Related Disease Treatment
Summary
USPTO published patent application US20260108528A1 on April 23, 2026, covering methods of treating RAS protein-related diseases using Compound A or a pharmaceutically acceptable salt thereof, including combination therapies with additional therapeutic agents. The application (No. 19363949) was filed October 21, 2025, naming nine inventors: Jingjing Jiang, Lingyan Jiang, Benjamin Maldonato, Mallika Singh, Sophia Sohoni, Zhengping Wang, Zhican Wang, Caroline E. Weller, and Muhammad Ali. CPC classifications include A61P 35/00 (antineoplastic) and various protein/antibody classifications, indicating cancer treatment applications.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108528A1 disclosing pharmaceutical compositions and methods of treating RAS protein-related diseases or disorders using Compound A or its pharmaceutically acceptable salt, including combination treatments with additional therapeutic agents. The application was filed October 21, 2025, under Application No. 19363949. CPC classifications (A61P 35/00, C07K 16/22, C07K 16/2818, C07K 16/2863) indicate oncology applications and therapeutic protein/antibody compositions.
Pharmaceutical companies developing RAS pathway inhibitors, oncology therapeutics, or related biologic treatments should review the application for potential freedom-to-operate considerations or licensing opportunities. Researchers in cancer therapeutics and targeted protein therapies may find this application relevant to their development programs. The publication does not constitute a granted patent and does not impose compliance obligations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER
Application US20260108528A1 Kind: A1 Apr 23, 2026
Inventors
Jingjing JIANG, Lingyan JIANG, Benjamin MALDONATO, Mallika SINGH, Sophia SOHONI, Zhengping WANG, Zhican WANG, Caroline E. WELLER, Muhammad ALI
Abstract
The disclosure features methods of treating RAS protein-related disease using Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS protein-related disease including combinations including Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agents.
CPC Classifications
A61K 31/5377 A61K 45/06 A61P 35/00 C07K 16/22 C07K 16/2818 C07K 16/2863
Filing Date
2025-10-21
Application No.
19363949
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.